NMNadia A. Mirza-Romero

Nadia A. Mirza-Romero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nadia A. Mirza-Romero has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhanced lysosomal activity prevents infection with PrPSc and the seeding activity of α-synuclein & tau prions

    by Robert C.C. Mercer, Nhat T.T. Le, Nadia A. Mirza-Romero, Isabel C. Orbe, Erin Flaherty, Joseph P. DeFranco, Giada Lavigna, Jean R.P. Gatdula, Douglas G. Fraser, Aravind Sundaravadivelu, et al.


  • Open Access

    Lysosomal Enhancement Prevents Infection with PrP Sc , α-Synuclein & Tau Prions

    by Robert C C Mercer, Nhat Tt Le, Nadia Mirza-Romero, Erin Flaherty, Giada Lavigna, Isabel C Orbe, Jean R P Gatdula, Douglas G Fraser, Aravind Sundaravadivelu, Janelle S Vultaggio, et al.

    Prion diseases are fatal neurodegenerative diseases of humans and other mammals with no current treatment options. Here, we describe the characterization of a novel anti-prion compound, elacridar (GW120918), which has sub-micromolar activity in assays of prion infection, propagation and toxicity. Elacridar acts at an early step in the prion infection process, enhancing degradation of newly formed PrP Sc . The lysosome is the likely site of elacridars anti-prion effects, based on transcriptomic analysis and the use of functional lysosomal probes. Elacridar alters gene expression networks controlling lysosomal sterol and lipid metabolism but, unlike other lysosomotropic drugs, it prominently upregulates genes that control lysosomal pH. Surprisingly, these effects occur independently of TFEB nuclear translocation, suggesting novel regulatory mechanisms. The anti-prion effects of elacridar extend to α-synuclein and tau prions, highlighting lysosomal enhancement as a general strategy for the treatment of protein misfolding neurodegenerative diseases.


  • Open Access

    Generation of Multivalent Nanobody-Based Proteins with Improved Neutralization of Long α-Neurotoxins from Elapid Snakes

    by Jack Wade, Charlotte Rimbault, Hanif Ali, Line Ledsgaard, Esperanza Rivera-De-Torre, Maher Abou Hachem, Kim Boddum, Nadia Mirza, Markus-Frederik Bohn, Siri A. Sakya, et al.

    Recombinantly produced biotherapeutics hold promise for improving the current standard of care for snakebite envenoming over conventional serotherapy. Nanobodies have performed well in the clinic, and in the context of antivenom, they have shown the ability to neutralize long α-neurotoxins in vivo. Here, we showcase a protein engineering approach to increase the valence and hydrodynamic size of neutralizing nanobodies raised against a long α-neurotoxin (α-cobratoxin) from the venom of the monocled cobraNaja kaouthia. Based on the p53 tetramerization domain, a panel of anti-α-cobratoxin nanobody-p53 fusion proteins, termed Quads, were produced with different valences, inclusion or exclusion of Fc regions for endosomal recycling purposes, hydrodynamic sizes, and spatial arrangements, comprising up to 16 binding sites. Measurements of binding affinity and stoichiometry showed that the nanobody binding affinity was retained when incorporated into the Quad scaffold, and all nanobody domains were accessible for toxin binding, subsequently displaying increased blocking potency in vitro compared to the monomeric format. Moreover, functional assessment using automated patch-clamp assays demonstrated that the nanobody and Quads displayed neutralizing effects against long α-neurotoxins from both N. kaouthia and the forest cobra N. melanoleuca. This engineering approach offers a means of altering the valence, endosomal recyclability, and hydrodynamic size of existing nanobody-based therapeutics in a simple plug-and-play fashion and can thus serve as a technology for researchers tailoring therapeutic properties for improved neutralization of soluble targets such as snake toxins.